INTS news

Latest 1 stories · newest Nov 5, 2026

INTS

Intensity Therapeutics Enrolls Patients in INVINCIBLE-3 and INVINCIBLE-4

Intensity Therapeutics resumed patient enrollment in two key oncology studies, INVINCIBLE-3 for soft tissue sarcoma and INVINCIBLE-4 for TNBC. The company reported $8.5 million in cash as of September 30, 2026.

Earnings|Guidance|Other Nov 5, 2026 sentiment +0.30 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same INTS feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/INTS/newsSTART FREE